D3 receptor compounds for the treatment of psychostimulant abuse

Project: Research project

Description

1. RR Luedtke, PhD. University of North Texas Health Science Center (UNTHSC) Dr. Luedtke will act as the PI for this grant proposal. He will manage the progress of the research project. This will be achieved through frequent communications and meetings between the PI with Co- Investigators. The primary subject of these discussions will focus on the scientific progress of the projects, including a) factors that might limiting the rate of progress of the program, b) special needs of projects and c) the training of staff, graduate students and/or post doctoral associates involved in this research project. This will be accomplished by monthly to bi-monthy conference calls with all investigators participating and monthly phone calls with Drs. Luedtke, Blass and Mach to discuss the progress of the medicinal chemistry/ADME &PK/molecular pharmacology studies. In addition, there will be a yearly meeting of all investigators and post doctoral fellows to present and discuss data, which will be held at one of the the institution locations involved in this application (Fort Worth, Philadelphia or Tempe). The PI will also be responsible for the management the fiscal aspects of the grant and oversee all fiscal aspects related to this research project, in conjunction with the UNTHSC Office of Grants and Contract Management. In addition, Dr. Luedtke will supervise and be directly involved in a) the Molecular Pharmacology (binding and functional selectivity) studies described in the grant application, b) coordinating, writing and submitting yearly NIH/NIDA Progress Reports and c) the timely submission of abstracts for scientific meeting and manuscripts for publication in peer-reviewed scientific journals. 2. B Blass, PhD. Temple University Shool of Pharmacy (TUSP) Dr, Blass, who is a Co-Investigator for this application, will oversee both the ADME and PK studies described in this application. Based upon those results, he will be involved in all decisions as to which compounds will be advanced for a) more detailed pharmacological analysis, b) more detailed ADME and PK analysis and b) in vivo behavioral studies. Dr. Blass will, of course, be directly involved in the writing and supervision of the writing of medicinal chemistry manuscripts. He will also participate in the review of all manuscripts related to this grant prior to submission for publication. 3. RH Mach, PhD. Washington University School of Medicine (WUSM) Dr. Mach, who is a Co-Investigator for this application, will direct and oversee the synthetic design and synthesis of the novel compounds proposed in this application. He will be involved in all decisions as to which compounds will be advanced for a) more detailed pharmacological analysis, b) more detailed ADME and PK analysis and b) in vivo behavioral studies. In addition, he is responsible for the synthesis of compounds in quantities required for in vivo studies. Dr. Mach will, of course, be directly involved in the writing and supervision of the writing of medicinal chemistry manuscripts. He will also participate in the review of all manuscripts related to this grant prior to submission for publication. 4. JL Neisewander, PhD. Arizona State University (ASU) Dr. Neisewander, who is a Co-Investigator for this application, will be responsible for the design and execution of all of the rodent behavioral assessments described in this application. This includes a) preparation of protocols submitted and approved by Arizona State Universitys Institutional Animal Care and Use Committee (IACUC) and b) supervision of stocks and record-keeping for psychostimulants. Dr. Neisewander will be involved in all decisions as to which compounds will be advanced for in vivo behavioral studies. Dr. Neisewander will, of course, be directly involved in the writing and supervision of the writing of manuscripts related to the behavioral studies. She will also participate in the review of all manuscripts related to this grant prior to submission for publication.
StatusFinished
Effective start/end date2/15/1511/30/19

Funding

  • HHS-NIH: National Institute on Drug Abuse (NIDA): $539,680.00

Fingerprint

Manuscripts
Organized Financing
Research Personnel
Pharmaceutical Chemistry
Publications
Pharmacology
Therapeutics
Animal Care Committees
Research
Health
Contracts
D3 compound
Rodentia
Communication
Medicine
Students